

**Brilliant Violet 605™ anti-human IL-17A**

**Catalog # / Size:** 3161625 / 25 tests  
3161630 / 100 tests

**Clone:** BL168

**Isotype:** Mouse IgG1, κ


**Immunogen:** Recombinant full length human IL-17A

**Reactivity:** Human

**Preparation:** The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 605™ and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

**Concentration:** Lot-specific




PMA + ionomycin-stimulated (6 hours) human peripheral blood lymphocytes (in the presence of monensin) were stained with CD3 FITC, fixed, permeabilized and then stained with IL-17A (clone BL168) Brilliant Violet 605™ (top) or mouse IgG1, κ Brill

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.



Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. **Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.** Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the

buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

**Application  
References:**

1. Bending D, *et al.* 2014. *J Immunol.* 193:2699. [PubMed](#)
- 

**Description:**

IL-17A is the founding member of the IL-17 family, a group of six structurally related pro-inflammatory cytokines. IL-17A, secreted by activated CD4<sup>+</sup> Th17 cell subpopulation, elicits multiple biological activities on a variety of cells including: the induction of IL-6, IL-8, G-CSF, and PGE2 production in epithelial, endothelial or fibroblasts; the enhancement of surface expression of ICAM-1 in fibroblasts; activation of NF-κB and costimulation of T cell proliferation. Recent studies demonstrated that, in mice, activated IL-17-secreting CD4<sup>+</sup> helper T cells (Th17 cells) mediate an autoimmune arthritis that clinically and immunologically resembles rheumatoid arthritis (RA). Human IL-17A shows 63%, 63%, and 72% amino acid sequence identity to rat IL-17A, mouse IL-17A, and a protein encoded by the ORF13 gene of herpesvirus Saimiri (HVS), respectively.

**Antigen  
References:**

1. Hirota K, *et al.* 2007. *J. Exp. Med.* 204:41.
2. Furuzawa-Carballeda J, *et al.* 2007. *Autoimmun. Rev.* 6:169.
3. Witowski J, *et al.* 2007. *Kidney Int.* 71:514.
4. Gaffen SL, *et al.*